Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 studyDo‐Youn Oh, Juan W. Valle, Choong‐kun Lee et al.|The Lancet. Gastroenterology & hepatology|2024Cited by 245